D.A. Davidson & CO. Acquires 87,230 Shares of Pfizer, Inc. (PFE)

D.A. Davidson & CO. raised its stake in shares of Pfizer, Inc. (NYSE:PFE) by 14.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 699,442 shares of the biopharmaceutical company’s stock after buying an additional 87,230 shares during the period. D.A. Davidson & CO.’s holdings in Pfizer were worth $23,683,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.6% in the second quarter. Vanguard Group Inc. now owns 383,339,513 shares of the biopharmaceutical company’s stock valued at $13,497,386,000 after buying an additional 6,193,821 shares during the period. Northern Trust Corp boosted its position in shares of Pfizer by 0.7% in the third quarter. Northern Trust Corp now owns 82,281,610 shares of the biopharmaceutical company’s stock valued at $2,786,877,000 after buying an additional 592,775 shares during the period. LSV Asset Management boosted its position in shares of Pfizer by 0.7% in the third quarter. LSV Asset Management now owns 35,329,679 shares of the biopharmaceutical company’s stock valued at $1,196,616,000 after buying an additional 260,500 shares during the period. Fisher Asset Management LLC boosted its position in shares of Pfizer by 0.4% in the third quarter. Fisher Asset Management LLC now owns 31,836,368 shares of the biopharmaceutical company’s stock valued at $1,078,298,000 after buying an additional 111,838 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of Pfizer by 1.1% in the second quarter. Legal & General Group Plc now owns 29,701,381 shares of the biopharmaceutical company’s stock valued at $1,045,726,000 after buying an additional 315,586 shares during the period. Hedge funds and other institutional investors own 69.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer, Inc. (NYSE:PFE) opened at 32.75 on Wednesday. The stock has a 50 day moving average price of $32.27 and a 200-day moving average price of $33.00. Pfizer, Inc. has a 1-year low of $28.74 and a 1-year high of $37.39. The company has a market capitalization of $198.74 billion, a price-to-earnings ratio of 27.92 and a beta of 0.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. The company earned $13.60 billion during the quarter, compared to analyst estimates of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. Pfizer’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.53 earnings per share. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Investors of record on Friday, February 3rd will be paid a $0.32 dividend. The ex-dividend date is Wednesday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.30. This represents a $1.28 dividend on an annualized basis and a yield of 3.91%. Pfizer’s dividend payout ratio is presently 110.35%.

This article was originally posted by sleekmoney and is owned by of sleekmoney. If you are reading this article on another publication, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The original version of this article can be read at http://sleekmoney.com/d-a-davidson-co-acquires-87230-shares-of-pfizer-inc-pfe/1661855.html.

Several equities analysts have recently issued reports on PFE shares. Guggenheim started coverage on Pfizer in a research report on Friday, December 2nd. They set a “neutral” rating on the stock. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research report on Tuesday, January 3rd. Vetr lowered Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.47 price objective for the company. in a research note on Monday, February 6th. Bank of America Corporation reissued a “buy” rating and set a $36.00 price objective (down from $40.00) on shares of Pfizer in a research note on Monday, November 7th. Finally, Morningstar, Inc. reissued a “buy” rating on shares of Pfizer in a research note on Thursday, February 2nd. Thirteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.15.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/d-a-davidson-co-acquires-87230-shares-of-pfizer-inc-pfe/1661855.html

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *